Skip to main content

Advertisement

Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms

Fig. 6

Effects of ZT55 on hematopoietic colony growth of MPN patients with activating JAK2V617F mutation. (a) Total and phosphorylated levels of JAK2, STAT3, and STAT5 were determined by western blot in peripheral blood mononuclear cells isolated from MPN patients harboring JAK2V617F mutations in the presence of indicated concentrations of ZT55. (b) Inhibitory efficacy (IC50) of ZT55 on BFU-E colony growth of cells derived from normal healthy volunteers or MPN patients harboring JAK2V617F mutations was determined, each value represents each MPN patient’s BFU-E measured IC50 in triplicate. (c) Cytokine-supported colony growth of erythroid cells (BFU-E, red bars), granulocytes (CFU-G, yellow bars) or granulocyte-macrophage progenitors (CFU-GM, black bars) from MPN patients harboring JAK2V617F mutations with the indicated concentrations of ZT55. Error bars indicate the SEM of mean values from three independent specimens measured in triplicate. (d) Representative photomicrographs of colonies derived from MPN patients’ cells plated in methylcellulose supplemented with cytokines are shown in various concentrations of ZT55 (a: 0 μM, b:12.5 μM, c:25 μM, d:50 μM), bar = 50 μm

Back to article page